文献速递妇科

淋巴结评估是否改变子宫内膜样癌中大量LVSI和p53状态的预后意义?

Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma?
PubMed 文献 · Gynecol Oncol · 2023-09-09

该回顾性研究纳入126例接受淋巴结评估的子宫内膜样癌患者,分析大量淋巴血管间隙浸润(LVSI)和p53异常表达的预后价值。中位随访37.2个月,p53异常和LVSI患者总生存更差,局部复发累积 incidence 更高。作者认为这些高危患者可能从外照射放疗强化中获益。

要点

  • p53异常表达患者死亡比例16.7%,野生型3.1%,差异有统计学意义。
  • LVSI阳性患者死亡比例11.1%,阴性1.5%,差异有统计学意义。
  • LVSI阳性2年区域复发累积 incidence 6.9%,阴性0%(p=0.05)。

核心结论

  • 尽管进行了淋巴结评估,具有p53异常表达和/或LVSI的高中危早期或IIIC期(仅有淋巴结阳性而无其他II/III期危险因素)子宫内膜样癌患者预后更差。
  • 作者认为这些患者可能从外照射放疗(EBRT)强化中获益,以改善局部和盆腔控制。

研究设计与样本

  • 回顾性综述126例FIGO 2009 IA期3级、IB期1-2级和IIIC期(淋巴结阳性但无其他II/III期危险因素)子宫内膜样癌患者,均接受淋巴结评估。
  • 采用竞争风险方法分析局部复发、区域复发和远处转移,Kaplan-Meier法分析总生存。

主要发现

  • 中位随访37.2个月。
  • p53异常表达患者死亡比例16.7%,p53野生型患者3.1%,差异有统计学意义(p<0.01)。
  • LVSI阳性患者死亡比例11.1%,LVSI阴性患者1.5%,差异有统计学意义(p<0.01)。
  • p53异常表达患者2年局部复发累积 incidence 11.1%(95%CI 0-25.6),p53野生型患者2.2%(95%CI 0-5.25),p=0.04。
  • LVSI阳性患者2年局部复发累积 incidence 11.4%(95%CI 2.0-20.9),LVSI阴性患者0%,p<0.01;LVSI阳性患者2年区域复发累积 incidence 6.9%(95%CI 0-14.4),LVSI阴性患者0%,p=0.05。

关键数值与推荐

  • p53异常表达患者2年局部复发累积 incidence 11.1%(95%CI 0-25.6),p53野生型患者2.2%(95%CI 0-5.25),p=0.04。
  • LVSI阳性患者2年局部复发累积 incidence 11.4%(95%CI 2.0-20.9),LVSI阴性患者0%,p<0.01。
  • LVSI阳性患者2年区域复发累积 incidence 6.9%(95%CI 0-14.4),LVSI阴性患者0%,p=0.05。

临床怎么用

  • 作者认为具有p53异常表达和/或LVSI的高中危早期或IIIC期子宫内膜样癌患者可能从外照射放疗强化中获益,以改善局部和盆腔控制。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The PORTEC-2 update suggested that substantial lymphovascular space invasion (LVSI) and abnormal p53 expression (p53abnl) predict for poorer outcomes and that these patients should be treated with external beam radiation therapy (EBRT). We aim to determine if patients with these risk factors who undergo a lymph node (LN) assessment show similar outcomes. METHODS: We retrospectively reviewed 126 patients with FIGO 2009 stage IA grade 3, stage IB grade 1-2, and stage IIIC (positive LN but no other stage II/III risk factors) endometrioid endometrial cancer who underwent LN assessment. Local (LR), regional recurrences (RR), and distant metastases were analyzed using competing risk methods, and overall survival (OS) was analyzed using Kaplan-Meier. RESULTS: Median follow-up time was 37.2 months. OS was significantly different between patients with and without p53abnl expression (16.7% versus 3.1% deceased), and between patients with and without LVSI (11.1% versus 1.5% deceased; p < 0.01 for both). The 2-year cumulative incidence of LR for patients with p53abnl versus wild type p53 and LVSI versus no LVSI was 11.1% (95% CI 0-25.6) versus 2.2% (95% CI 0-5.25; p = 0.04), and 11.4% (95% CI 2.0-20.9) versus 0%, respectively (p < 0.01). The 2-year cumulative RR in patients with LVSI versus no LVSI was 6.9% (95% CI 0-14.4) versus 0% (p = 0.05). No patients who completed pelvic RT experienced an in-field recurrence. CONCLUSIONS: Despite LN assessment, patients with high-intermediate risk early-stage or stage IIIC (with positive lymph nodes only but no other stage II or III risk factors) endometrial cancer with p53abnl expression and/or LVSI have worse outcomes. These patients may derive benefit from intensification with EBRT to improve local and pelvic control.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hui C, Mendoza MG, von Eyben R, et al. Does lymph node assessment change the prognostic significance of substantial LVSI and p53 status in endometrial endometrioid carcinoma? Gynecol Oncol. 2023. PMID: 37696217. doi:10.1016/j.ygyno.2023.09.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。